Rosa & Co. Partners with MathWorks to Advance Quantitative Systems Pharmacology

Rosa & Co. Partners with MathWorks to Advance Quantitative Systems Pharmacology

Leading biological modeling company teams up with leading mathematical software provider to facilitate model-informed drug development.

SAN CARLOS, Calif., Sept. ­18, 2015 /PRNewswire/ -- Rosa & Co. LLC, the leading commercial drug development advisory firm with expertise in Quantitative Systems Pharmacology (QSP)/ PhysioPD™, today announced a co-marketing agreement with MathWorks, developer of mathematical computing software and maker of MATLAB, SimBiology and Simulink. The agreement between MathWorks and Rosa will provide drug development professionals examples of how to address real world challenges using state-of-the-art software tools and proven QSP modeling approaches.

Logo - http://photos.prnewswire.com/prnh/20150917/267629LOGO

SimBiology, a computational biology software product from MathWorks, will now be one of the software products used by Rosa & Co. to build PhysioPD Research Platforms for pharmaceutical research and development.  The agreement aligns the companies' efforts to advance the field of QSP.  Rosa & Co. and MathWorks will jointly create case studies, webinars, and workshops utilizing Rosa's expertise in PhysioPD modeling and biological research while employing SimBiology and/or other MathWorks' products for QSP modeling. Topics will include applications, philosophy and Rosa's Model Qualification Method, as well as tools and hands-on model implementation and analysis in SimBiology and MATLAB. The agreement extends Rosa's clients' choices for quality software tools for pharmaceutical research and development.  Researchers will gain information on how to build QSP models to help enhance scientific insight and decision support applicable to all therapeutic areas across the entire drug development pipeline.

"We are pleased to combine our PhysioPD experience with MathWorks' scientific computing expertise to create better tools for research and case studies of real-world applications.  This is a pivotal moment in the QSP field.  We hope to make a substantive contribution toward much broader adoption of QSP throughout the pharmaceutical industry.

- Dr. Christina Friedrich, Chief Engineer, PhysioPD, Rosa & Co. LLC

"Systems modeling has the potential to significantly improve drug development.  We are excited to team up with Rosa & Co. to help meet this promise by integrating our complementary expertise in drug development, modeling and mathematical software to make system modeling tools suitable to the practical needs of the QSP community."

- Ricardo Paxson, Director Computational Biology, MathWorks Inc.

About Rosa
Rosa supports clients with their critical decisions - from preclinical through clinical development - by creating and using customized innovative PhysioPD™ Research Platforms that simulate normal and disease physiology, drug action, patient variability, and trial outcomes, thereby addressing the full spectrum of R&D related challenges from targets to outcomes. Rosa's clients are involved in Platform creation, testing, and biological simulation research. Clients retain the Platform as a program asset to support decisions and future research. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to accelerate drug development and has over 13 years of client engagements in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area experience, including metabolic diseases, immuno-oncology, oncology, cardiovascular, inflammation, immune dysfunction, central nervous system disorders, dermatology, and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com/news.html          

Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
PhysioPD is a trademark of Rosa & Co. LLC.

MATLAB and Simulink are registered trademarks of The MathWorks, Inc. See mathworks.com/trademarks for a list of additional trademarks. Other product or brand names may be trademarks or registered trademarks of their respective holders.

Media Contact:
Stephanie Sherman
425-591-5738
Email

 

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.